Clinical Trial Sponsors (drug pipelines)
Regulated market (drugs@fda application holders) + trial-register participation (clinicaltrials.gov, eu ctis) + standards-body membership (cdisc). The Kin Score Market layer reads each provider in its market: who it integrates with, how deep those integrations go, and where the market publishes its own structure. Methodology.
Where this market publishes its structure
- ClinicalTrials.gov API v2 (interventional, started >= 2021, industry lead sponsor or collaborator) machine-readable, 43,972 studies / 10,267 industry names; participation only; 459 linked
- Drugs@FDA (openFDA drug/drugsfda bulk download; sponsor_name = application holder) machine-readable, 29,404 applications / 2,253 holders; names only; 36 linked; one certified product per application type
- EU CTIS public search (euclinicaltrials.eu/ctis-public-api/search, the page's own public JSON) machine-readable, 12,681 trials (10,000-row cap per query, read newest + oldest); 1,802 pharmaceutical-company sponsors; 158 linked
- CDISC member search (cdisc.org/members/search + public /company/ page website) machine-readable, 390 members, 374 with website; 34 linked by domain + name; the given URL /membership/member-list returns 404
Own = declares at least one integration itself; covered = visible only because an aggregator, standards body, regulator or partner contract names it; distribution-only = listed only on cloud marketplaces it sells through, a channel reported beside, never counted as its own declared integrations; undeclared = nothing we can read, so no number; declares_compatibility = providers with a `compatible` shape vote, report only (kin, 2026-10-13): never counted as own, never in depth or position.
Taxonomy how this market maps onto apis.io
Derived 2026-10-23 from the 55 providers in this market we could resolve in the catalog. The percentage is the share of those providers carrying each one; it describes the market, not the tag or industry. Tag groups have no page of their own yet, so they are listed unlinked.
| Tags | Pharmaceuticals 71%, Healthcare 65%, Life Sciences 64%, Biotechnology 55%, Clinical Trials 40%, Oncology 24% |
|---|---|
| Tag groups | Healthcare 96%, Health 25% |
| Industries | Biotechnology & Drug Discovery 80%, Pharmaceutical 76%, Healthcare 71%, Life Sciences 64%, Digital Health & Telehealth 33% |
share of resolved cohort carrying it; tags >=0.20 & >=3 members (max 12, junk dropped), tag_groups >=0.20 (cooccurrence, non-cross-cutting; max 8), industries >=0.20 (max 6), areas >=0.10 (max 6; areas are keyword-matched and sparse), capabilities L1 >=0.20 (max 8); derive-market-taxonomy.py
Leaders by position (provisional)
Provisional: grouped by position, depth compared within a position only. Distribution (cloud marketplaces) and iPaaS bridges are counted beside position, never inside it. Unknown-builder listings are left out of position shares and counted here.
regulated 16 · named in a regulator's register or partners' contracts
| Provider | Depth | Integrations | In / out | Unknown builder | Distribution | iPaaS bridge | Mix |
|---|---|---|---|---|---|---|---|
| Viatris | 63.8 | 3 | 0 / 3 | 0 | 0 | 0 | contract 67%, standard 33% |
| Organon | 61.7 | 4 | 0 / 4 | 0 | 0 | 0 | contract 50%, standard 50% |
| AbbVie | 61.6 | 7 | 0 / 7 | 0 | 0 | 0 | contract 57%, standard 43% |
| Novo Nordisk | 59.9 | 6 | 0 / 6 | 0 | 0 | 0 | contract 50%, standard 50% |
| Eli Lilly | 58.5 | 10 | 0 / 10 | 0 | 0 | 0 | contract 50%, standard 50% |
| Johnson & Johnson | 57.9 | 3 | 0 / 3 | 0 | 0 | 0 | contract 67%, standard 33% |
| Insmed | 56.4 | 4 | 0 / 4 | 0 | 0 | 0 | contract 50%, standard 50% |
| Sibel Health | 55.6 | 3 | 0 / 3 | 0 | 0 | 0 | contract 67%, standard 33% |
| Bayer | 53.5 | 7 | 0 / 7 | 0 | 1 | 0 | contract 43%, standard 43%, distribution 14% |
| Hospira | 43.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | contract 50%, standard 50% |
| Sunshine Lake Pharma | 41.1 thin | 2 | 0 / 2 | 0 | 0 | 0 | contract 50%, standard 50% |
| Beacon Biosignals | 38.8 thin | 2 | 0 / 2 | 0 | 0 | 0 | contract 50%, standard 50% |
| Intersect ENT | 38.8 thin | 2 | 0 / 2 | 0 | 0 | 0 | contract 50%, standard 50% |
| Neurelis | 38.8 thin | 2 | 0 / 2 | 0 | 0 | 0 | contract 50%, standard 50% |
| Orapharma | 38.8 thin | 2 | 0 / 2 | 0 | 0 | 0 | contract 50%, standard 50% |
| Zurex Pharma | 38.8 thin | 2 | 0 / 2 | 0 | 0 | 0 | contract 50%, standard 50% |
standard 38 · listed by a voluntary standard's own directory
| Provider | Depth | Integrations | In / out | Unknown builder | Distribution | iPaaS bridge | Mix |
|---|---|---|---|---|---|---|---|
| Pfizer | 61.8 | 7 | 0 / 7 | 0 | 0 | 0 | contract 43%, standard 57% |
| Celgene | 61.1 | 5 | 0 / 5 | 0 | 0 | 0 | contract 40%, standard 60% |
| Sanofi | 59.7 | 5 | 0 / 5 | 0 | 0 | 0 | contract 40%, standard 60% |
| Novartis | 59.3 | 7 | 0 / 7 | 0 | 0 | 0 | contract 43%, standard 57% |
| AstraZeneca | 58.4 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Gilead Sciences | 57.8 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Merck | 57.8 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Regeneron | 57.4 | 7 | 0 / 7 | 0 | 0 | 0 | contract 29%, standard 71% |
| Bristol Myers Squibb | 57.1 | 5 | 0 / 5 | 0 | 0 | 0 | contract 20%, standard 80% |
| Genentech | 56.7 | 4 | 0 / 4 | 0 | 0 | 0 | contract 25%, standard 75% |
| ADC Therapeutics | 56.0 | 3 | 0 / 3 | 0 | 0 | 0 | contract 33%, standard 67% |
| Amgen | 56.0 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Biogen | 56.0 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Chimerix | 56.0 | 3 | 0 / 3 | 0 | 0 | 0 | contract 33%, standard 67% |
| Epizyme | 56.0 | 3 | 0 / 3 | 0 | 0 | 0 | contract 33%, standard 67% |
| Vera Therapeutics | 56.0 | 3 | 0 / 3 | 0 | 0 | 0 | contract 33%, standard 67% |
| Verastem | 56.0 | 3 | 0 / 3 | 0 | 0 | 0 | contract 33%, standard 67% |
| Denali Therapeutics | 55.0 | 4 | 0 / 4 | 0 | 0 | 0 | contract 25%, standard 75% |
| Revolution Medicines | 55.0 | 4 | 0 / 4 | 0 | 0 | 0 | contract 25%, standard 75% |
| Apogee Therapeutics | 51.7 | 3 | 0 / 3 | 0 | 0 | 0 | standard 100% |
| Huma | 36.4 | 3 | 0 / 3 | 0 | 2 | 0 | standard 33%, distribution 67% |
| Abcuro | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| ADARx Pharmaceuticals | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| Endeavor BioMedicines | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| Engrail Therapeutics | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| Life Biosciences | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| NeuroTherapia | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| ReCode Therapeutics | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| A2 Biotherapeutics | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| AiCure | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Alloplex Biotherapeutics | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| CIONIC | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| JenaValve Technology | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Neomorph | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Schrödinger | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Scimar | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Strata Oncology | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Tune Therapeutics | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
mixed 1 · no single mode dominates
| Provider | Depth | Integrations | In / out | Unknown builder | Distribution | iPaaS bridge | Mix |
|---|---|---|---|---|---|---|---|
| Verily Life Sciences | 48.4 | 3 | 0 / 3 | 0 | 1 | 0 | contract 33%, standard 33%, distribution 33% |
Generated 2026-10-24 from API Evangelist's own files; nothing on this page is a model's judgement. Provisional and unweighted; not part of the Kin Score composite or agent readiness. Read the Market layer methodology. Disagree with an edge? Every edge cites its evidence and can be corrected through the normal correction path.